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Available online 18 November 2016Live attenuated vaccines (LAVs) offer strong cellular and
antibody responses for protecting at-risk populations from
severe infectious diseases.1 Examples include the measles,
mumps, herpes zoster, varicella, and yellow fever vaccines.
LAVs, however, are usually contraindicated for individuals
with immunocompromising (IC) conditions because of a low
risk, based on clinical evidence or theoretical considerations,
that the partially attenuated vaccine strain could revert to the
wild-type form and cause disease.2e4 At the same time, in-
dividuals with IC conditions need vaccines because they are at
an increased risk of severe infections.5e7 In cases where al-
ternatives to live vaccines are not available for individuals
with IC conditions, the risk of potential adverse events from
the vaccine must be weighed against the risk of disease from
the wild-type pathogen.
To make informed decisions about developing or offering
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0033-3506/© 2016 GlaxoSmithKline SA. Published by Elsevier Ltd on be
article under the CC BY-NC-ND license (http://creativecommons.org/the size of the IC population is needed. The only estimate to
date, published in 2001, suggested that close to 10 million in-
dividuals in theUSAor3.6%of thepopulationhad ICconditions,
although the authors explained that this was a ‘back of the en-
velope’ calculation based solely on the sum of the numbers of
organ transplants, individualswithdiagnosedandundiagnosed
human immunodeficiency virus/acquired immune deficiency
syndrome (HIV/AIDS) and patients with cancer.8
To better understand the unmet need for alternative vac-
cines in the adult IC population, we estimated the total burden
of 11 main IC conditions listed as contraindicated conditions
in international vaccination guidelines and recom-
mendations.9e12 The GLOBOCAN database13 was used for
cancer incidence and prevalence rates. For all other IC con-
ditions, incidence and prevalence rates were obtained by a
search of PubMed and, where data were unavailable, by a
search for surveillance data available online (Table 1). When
more than one source of data with the necessary age stratifi-
cation (18þ years) was available, we selected the one with the
highest quality, most representative data using a tool adapted
from the Effective Public Health Practice Project Quality
Assessment Tool for Quantitative Studies.14
Although our initial goal was to make estimates for 10
countries, our search of peer-reviewed articles and surveil-
lance databases yielded sufficient data only for the USA and
UK. Based on the data we collected, we estimated that in 2012,
7.6 million adults (18 years old) in the USA and 1.7 million
adults in the UK had one of the IC conditions listed in Table 1.ia, 150 Beach Road, #22-00 Gateway West, 189720, Singapore.
nd.
half of The Royal Society for Public Health. This is an open access
licenses/by-nc-nd/4.0/).
Table 1 e Incidence and prevalence of IC conditions in adults in the USA and UK.
IC conditiona Measure USA UK
No. per 100,000
persons or
person-years
Year Estimated
no. of casesb
No. per 100,000
persons or
person-years
Year Estimated
no. of
casesc
Solid organ malignancies Prevalence 362.05d 2012 869,593 320.79d 2012 160,977e
Incidence 460.57d 2012 1,106,224 443.29d 2012 222,448
Haematological malignancies Prevalence 35.14d 2012 84,401 33.31d 2012 16,715
Incidence 50.41d 2012 121,078 48.91d 2012 24,543
Psoriasis Prevalence 883f 1996e2009 2,120,842 1520.2g 1987e2002 919,502e
Incidence 78.9h 1970e1999 191,065e 140i 1996e1997 72,029e
Systemic lupus erythematosus Prevalence 143.75j 2000e2004 512,016e 49.31k 1998 24,746e
Incidence 7.22l 2003e2008 18,127e 3.02k 1992e1998 1,789e
Rheumatoid arthritis Prevalence 720m 1995e2007 1,729,339 570n 2010 286,029
Incidence 40.9m 1995e2007 99,195e 48o 1990e1995 20,881e
Crohn's disease Prevalence 96.3p 2002 308,683e 157q 2007 78,784
Incidence 6.3p 1996e2002 18,067e 9.56q 2003e2007 4,725e
Ulcerative colitis Prevalence 155.8p 2002 514,792e 243r 2002 121,939
Incidence 12.0p 1996e2002 36,496e ND ND ND
HIV/AIDS Prevalence 324.6s 2009 830,101e 150t 2012 75,271
Incidence 19.5s 2010 48,248e 10t 2012 5018
HSCT Prevalence ND ND ND ND ND ND
Incidence 4.0u 2006 9,607e ND ND ND
Solid organ transplant Prevalence ND ND ND ND ND ND
Incidence 10.9 2012 26,281v 9.27 2013e2014 4,655e,w
End-stage renal disease Prevalence 190.09x 2011 650,483e 86.32y 2011 55,624e
Incidence 35.71x 2011 123,125e 10.70z 2011 6,944e
Total Prevalence e e 7,620,252 e e 1,739,587
Incidence e e 1,797,512 e e 363,031
The GLOBOCAN database was used for cancer incidence and prevalence rates. For all other IC conditions, peer-reviewed articles in English
published in the last 5 years were identified by a search of PubMed on October, 2013 using the following search string: [IC condition] AND
(incidence OR prevalence) AND [country]. When more than one publication was found with the necessary age stratification (18þ years), data
from the highest quality study were selected using a tool adapted from the Effective Public Health Practice Project Quality Assessment Tool for
Quantitative Studies (http://www.ephpp.ca/tools.html). When data were not found in the initial search, the search was extended to the last 10
years. If data were still not found, they were obtained from online global surveillance databases when available, or if not, from country-specific
surveillance databases identified using the Google search engine. Abbreviations: HIV/AIDS, human immunodeficiency virus/acquired immune
deficiency syndrome; HSCT, haematopoietic stem cell transplant; ND, no data; Ref, reference; No: number; IC: immunocompromising.
a Included conditions were based on: Habel et al. Cancer Epidemiol Biomarkers Prev. 2013;22:82e90; US Centers for Disease Control and Prevention.
CDC Health Information for International Travel 2014. New York: Oxford University Press; 2014; Lupus Canada. Immunosuppressive drugs
used in treating lupus. 2007. Available from http://www.lupuscanada.org/pdfs/factsheets/Immuno-Online.pdf; Trevillian P. Australian Pre-
scriber. 2006;29:102e8; Centers for Disease Control and Prevention. MMWR Recomm Rep. 1993;42:1e18; Centers for Disease Control and Pre-
vention.MMWR Recomm Rep. 2011;60:1e64; Fiore et al.MMWR Recomm Rep. 2010; 59:1e62; and Harpaz et al.MMWR Recomm Rep. 2008;57:1e30.
b Based on the 2012 adult population in the USA (240,185,952). Source: http://factfinder.census.gov/faces/tableservices/jsf/pages/productview.
xhtml?src¼bkmk.
c Based on the 2012 adult population in the UK (50,180,600). Source: http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-
uk–england-and-wales–scotland-and-northern-ireland/mid-2011-and-mid-2012/rft—mid-2012-uk-population-estimates.zip.
d International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012.
Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
e Cases presented are based on age-standardized rates, which were calculated based on 2012 population data using age-specific rates reported
(where available) and the 2012 census data to estimate the cases for the 18 years old population.
f Asgari et al. Pharmacoepidemiol Drug Saf. 2013;22:842e9.
g Gelfand et al. Arch Dermatol. 2005;141:1537e41.
h Icen et al. J Am Acad Dermatol. 2009;60:394e401.
i Huerta et al. Arch Dermatol. 2007;143:1559e65.
j Feldman et al. Arthritis Rheum. 2013;65:753e63.
k Nightingale et al. Pharmacoepidemiol Drug Saf. 2006;15:656e61.
l Furst et al. Lupus. 2013;22:99e105.
m Myasoedova et al. Arthritis Rheum. 2010;62:1576e82.
n Jordan et al. Ann Rheum Dis. 2014;73:212e8.
o Humphreys et al. Ann Rheum Dis. 2013;72:1315e20.
p Herrinton et al. Am J Gastroenterol. 2008;103:1998e2006.
q Steed et al. Scott Med J. 2010;55:22e5.
r Stone et al. Eur J Gastroenterol Hepatol. 2003;15:1275e80.
s Prejean et al. J Community Health. 2013;38:414e26.
t Aghaizu et al. HIV in the United Kingdom: 2012 Report. London: Public Health England; 2012. Available from: https://www.gov.uk/government/
uploads/system/uploads/attachment_data/file/326601/HIV_annual_report_2013.pdf.
p u b l i c h e a l t h 1 4 2 ( 2 0 1 7 ) 4 6e4 9 47
u Gratwohl et al. JAMA. 2010;303:1617e24.
v Transplants in the U.S. by Recipient Age, 2012; Based on OPTN data as of August 1, 2015. Available from: http://optn.transplant.hrsa.gov/
converge/latestData/step2.asp.
w Transplant activity report (2014e2015) Table 2.4, Page 10. Available from: http://nhsbtmediaservices.blob.core.windows.net/organ-donation-
assets/pdfs/activity_report_2014_15.pdf.
x U.S. Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.
Bethesda, MD: National Institutes of Health; 2013. Available from: http://www.usrds.org/atlas.aspx.
y Shaw et al. Nephron Clin Pract. 2013; 125:29e53.
z Gilg et al. Nephron Clin Pract. 2013; 125:1e27.
p u b l i c h e a l t h 1 4 2 ( 2 0 1 7 ) 4 6e4 948This represents 3.17% of the total adult population in the USA
and 3.47% of the total adult population in the UK. Each year,
there are an estimated 1.8 million new cases of IC conditions
in the USA and 0.36 million in the UK.
These estimates are subject to differences in case ascer-
tainment, not to mention differences in data collection and
reporting for each condition. For example, the incidence and
prevalence rates for psoriasis were twice as high in the UK as in
the USA. Possible explanations are differences in case ascer-
tainment, demographics, geography, methodology, case defi-
nitionsanddefinitionsofprevalence. Inaddition,weusedonlya
single data source for incidence or prevalence in each country;
using alternative sources, especially for the more dominant IC
conditions like HIV/AIDS and malignancies, could have some
effect on the estimates. Regardless, the numbers for the IC
population in the USA are in line with the previous estimates,8
and the overall prevalence of IC conditions is similar for the
USA and UK, suggesting that our estimates are reasonable.
Not all subjectswith chronic conditions like systemic lupus
erythematosus, psoriasis, rheumatoid arthritis and inflam-
matory bowel disease will be on immune-suppressive treat-
ments at any point in time, but little data is available to
determine the corresponding proportions. Similarly, for HIV/
AIDS, not all subjects will be immunosuppressed at any given
time (i.e. CD4 counts <200) and, again, the proportion is diffi-
cult to determine from available data. To help address this
limitation, we tested a scenario in which half of patients with
these conditions are considered immunosuppressed at any
given time. Based on this assumption, and using the unaltered
estimates for the remaining conditions, the estimated number
of adults with IC conditions was 4.6 million in the USA (1.92%)
and 1.0 million in the UK (1.97%).
These estimates are only a first step in understanding how
many individuals with IC conditions require alternative vac-
cines. Many other variables must be considered, notably, the
causeandseverityof immunosuppressionforeach ICcondition,
which can vary greatly,15 and for individuals receiving immu-
nosuppressive treatments, the level and duration of immuno-
suppression for which LAVs should be contraindicated. In
addition, the nature of each infectious disease, the risk of
exposure to it and its associated morbidity must be considered
when determining who should or should not receive LAVs.
In summary, despite the limitations to our analysis and
lack of data for countries other than the USA and the UK, our
calculations suggest that roughly 2e3% of the global adult
population lives with an IC condition and might benefit from
alternative vaccines to LAVs. This estimate is meant as a
starting point for understanding themagnitude of the need for
alternatives to LAVs. Although the numbers and percentages
appear to be reasonable for the UK and the USA, and thereforeperhaps also for upper-income countries in general, they may
not be accurate for individual countries, especially lower-
income countries. Analyses of large datasets, coupled with
harmonized case ascertainment and data collection, as well
as additional country-specific data on disease burden are
needed to make more accurate estimates.Author statements
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